Mercado global de tratamento da hipertensão ocular – Tendências do setor e previsão para 2030

Análise e dimensão do mercado de tratamento da hipertensão ocular

De acordo com os registos de Outubro de 2021 da Organização Mundial de Saúde sobre cegueira e deficiência visual, prevê-se que quase 2,2 mil milhões de pessoas enfrentem distúrbios de visão para longe ou para perto. As doenças oculares surgiram como uma possível ameaça potencial para as populações de todos os países de rendimento médio e industrializados. As principais causas de deficiência visual incluem erros refrativos não corrigidos, degeneração macular relacionada com a idade, cataratas e muitas outras.

 A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de tratamento da hipertensão ocular no período de previsão 2023-2030. O CAGR esperado do mercado global de tratamento da hipertensão ocular tende a rondar os 3% no período de previsão mencionado. O mercado foi avaliado em 5,13 mil milhões de dólares em 2022 e cresceria até 6,5 mil milhões de dólares até 2030. Além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes no mercado e cenário de mercado, o mercado O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de tratamento da hipertensão ocular

Market Definition

Ocular hypertension happens when the eye's pressure (intraocular pressure or IOP) becomes higher than average. It instigates increased eye strain. Glaucoma may be caused by increased pressure than the normal eye pressure. Glaucoma is a type of condition in which eye pressure affects the optic nerve and leads to loss of vision. However, ocular hypertension is not similar to glaucoma. In this condition, the optic nerve looks normal and there are no signs of vision loss. Although, many people having ocular hypertension are at increased risk for glaucoma and are considered “glaucoma suspects.”

Global Ocular Hypertension Treatment Market Dynamics

Drivers

• Increase in elderly population

The global ocular hypertension treatment market is projected to witness a heavy growth rate during the forecast period driven by the factor of an aging population. The growing demand in the global ocular hypertension treatment market is the replication of the rising elderly population, as people aged over 60 years normally develop conditions wherein the eyes have reduced elasticity, affecting the normal functioning. This boost the market growth.

• Advanced technological advancements

Increasing technological advancements associated with the ocular hypertension treatment and diagnostics are boosting the growth of the market. Technologies such as medical imaging, selective laser trabeculoplasty (SLT), visual fields, micro-invasive glaucoma surgery (MIGS), optical coherence tomography (OCT), and progression analysis software will increase patient preference. Moreover, the market size will increase if laser therapies are combined with medications to treat glaucoma as the first-line therapy. This boosts the market growth

Opportunities

• Rising strategic initiatives

The strategic initiatives that major key players undertake is projected to increase the market growth. For instance, in June 2022, Novartis Pharmaceuticals Corporation announced the acquisition of Kedalion Therapeutics for its novel AcuStream technology. This acquisition pushed Novartis to boost its ophthalmic product portfolio. In addition to this, in June 2022 Amring Pharmaceuticals Inc. announced that its generic Timolol Maleate Ophthalmic Solution has received approval from the U.S FDA. Timolol Maleate Ophthalmic Solution is a preservative-free solution and is recommended in the treatment of open-angle glaucoma and ocular hypertension.

• Increasing R&D activities

Increasing research and development activities and expenditure by top market players is expected to increase the market growth during the projected period. For an instance, Alcon, a leader in eye care spent USD 842 million on R&D in 2021 as compared to USD 673 million in 2020. Alcon provides an extensive range of products such as contact lenses, cataracts, and glaucoma products. Thus, all these increasing healthcare expenditures create many market growth opportunities.

 Restraints/Challenges

• Lack of skilled professionals

The lack of skilled healthcare professionals who are unable to treat the patients with appropriate treatments could restrain the growth of the global ocular hypertension treatment market over a forecast period.

• High cost

The huge expenditure associated with the treatment of ocular hypertension hamper the market growth. The treatment involves various types of surgery and costly diagnostic procedures that somewhat hinder the market growth.

This global ocular hypertension treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ocular hypertension treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Ocular Hypertension Treatment Market           

The Covid-19 pandemic significantly affected the market due to a reduction in number of patient visits in hospitals and clinics for ocular disorders and interruption of numerous alternative procedures and outpatient visits. For instance, as per the records of Clinical Ophthalmology Journal, in November 2021, in the analysis of post-pandemic and pre-pandemic data, it can be expected that visual field checkups, medications released, clinical visits, and surgical procedures declined 93.84%, 19.63%, ,92.52%, and 72.74% at the time when pre and post-pandemic times were compared. Thus, the data tells that the treatment of glaucoma and other ophthalmic disorders reduced considerably. Though, the market is projected to witness a spike due to the wide availability of COVID-19 vaccines and decreasing COVID-19 cases.

Global Ocular Hypertension Treatment Market Scope

The global ocular hypertension treatment market is segmented on the basis of type, route of administration , drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Intraocular Hypertension
• Glaucoma

Route of Administration

• Oral
• Parenteral
• Others

Drug Type

• Prescription
• Over the Counter

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Ocular Hypertension Treatment Market Regional Analysis/Insights

The global ocular hypertension treatment market is analyzed and market size insights and trends are provided by type, route of administration, drug type, distribution channel and end-user as referenced above.

The major countries covered in the global ocular hypertension treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Shypertension treatment, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global ocular hypertension treatment market throughout the forecasted period due to the highest number of geriatric and vulnerable populations.

North America dominates the market due to the increase in research & development activities for the development of novel therapies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Ocular Hypertension treatment Market Share Analysis

The global ocular hypertension treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global ocular hypertension treatment market.

Key players operating in the global ocular hypertension treatment market include:

• Aerie Pharmaceuticals, Inc. (U.S.)
• Abbvie, Inc (U.S.)
• Angelini Pharma S.p.a.(Italy)
• Chong Kun Dang pharmaceutical Corp (South Korea)
• Laboratorios Sophia (Mexico)
• Lee Pharma Ltd (Hong Kong)
• Neurim Pharmaceuticals LTD (Israel)
• Nicox (France)
• Novartis AG (Switzerland)
• Ocular Therapeutix, Inc. (U.S.)
• Sylentis, S.A (Spain)
• Taejoon Pharm (South Korea)
• Takeda Pharmaceutical Company Limited (Japan)
• Bausch Health Companies Inc. (Canada.),
• Merck & Co. Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)

Research Methodology: Global Ocular Hypertension Treatment Market     

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (Factbook) ou pode ajudá-lo na criação de apresentações a partir dos conjuntos de dados disponíveis no relatório.

SKU-55973